pharmaceutical investing Rhythm Pharmaceuticals Announces Launch of TEMPO Registry for Rare Genetic Disorders of Obesity
pharmaceutical investing Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity
pharmaceutical investing Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials
